CORMAX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cormax, and when can generic versions of Cormax launch?
Cormax is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in CORMAX is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cormax
A generic version of CORMAX was approved as clobetasol propionate by COSETTE on February 16th, 1994.
Summary for CORMAX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Patent Applications: | 4,476 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CORMAX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CORMAX
US Patents and Regulatory Information for CORMAX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | CORMAX | clobetasol propionate | CREAM;TOPICAL | 074220-001 | May 16, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |